JPH05246875A - Agent for improving and treating diabetes - Google Patents
Agent for improving and treating diabetesInfo
- Publication number
- JPH05246875A JPH05246875A JP4084730A JP8473092A JPH05246875A JP H05246875 A JPH05246875 A JP H05246875A JP 4084730 A JP4084730 A JP 4084730A JP 8473092 A JP8473092 A JP 8473092A JP H05246875 A JPH05246875 A JP H05246875A
- Authority
- JP
- Japan
- Prior art keywords
- diabetes
- improving
- extract
- asparagus
- linearis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 241001219293 Aspalathus Species 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 4
- 238000009835 boiling Methods 0.000 abstract description 3
- 238000004108 freeze drying Methods 0.000 abstract description 2
- 241000234427 Asparagus Species 0.000 abstract 3
- 235000005340 Asparagus officinalis Nutrition 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 241000220485 Fabaceae Species 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 235000013361 beverage Nutrition 0.000 abstract 1
- 238000000605 extraction Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 235000003884 Aspalathus contaminatus Nutrition 0.000 description 1
- 240000006914 Aspalathus linearis Species 0.000 description 1
- 235000012984 Aspalathus linearis Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000014112 Cassia mimosoides Nutrition 0.000 description 1
- 244000302899 Cassia mimosoides Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、マメ科に属するアスパ
ラサス・リネアリスの含有成分を有効成分とする糖尿病
改善治療剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a therapeutic agent for diabetes mellitus, which contains, as an active ingredient, a component of Aspalathus linealis belonging to the legume family.
【0002】[0002]
【従来の技術】近年、糖尿病は中年者とか高年者だけで
なく若年者にも尿中に糖(グルコース)がでる糖尿病者
が数多く表れ社会問題にもなってきている。糖尿病には
インシュリン投与によって治療効果の上がるインシュリ
ン依存型糖尿病とインシュリン投与で大きな効果の現れ
ない非インシュリン依存型糖尿病がある。2. Description of the Related Art In recent years, diabetes has become a social problem because not only middle-aged and elderly people but also young people have many diabetics with glucose in their urine. Diabetes mellitus includes insulin-dependent diabetes mellitus whose therapeutic effect is improved by insulin administration and non-insulin-dependent diabetes mellitus in which insulin administration does not show a significant effect.
【0003】[0003]
【発明が解決しようとする課題】しかし、従来より、非
インシュリン依存型糖尿病は適当な治療法が無く、食事
療法あるいは運動療法がなされているが、患者の意志の
強さに左右されることが多く、効果が薄く糖尿病を安定
的に治療するのは難しい。However, conventionally, non-insulin-dependent diabetes mellitus has no appropriate therapeutic method and diet or exercise therapy is used, but it depends on the strength of the patient's will. Many have little effect and it is difficult to treat diabetes stably.
【0004】また、日常強い意志を必要とせず日常通常
人と同様に飲食する事で、糖尿病を安定化する治療薬は
知られていない。[0004] Further, there is no known therapeutic drug that stabilizes diabetes by eating and drinking in the same way as a normal person in daily life without requiring a strong will.
【0005】本発明は、前記課題を解決し、糖尿病を日
常経口的に摂取することで、有効な症状の改善治療剤を
提供することを目的とする。An object of the present invention is to solve the above problems and to provide an effective therapeutic agent for improving symptom by ingesting diabetes daily orally.
【0006】そこで、本発明者らは、前記目的を達成す
るために鋭意研究を重ねた結果、マメ科に属するアスパ
ラサス・リネアリス抽出物が、糖尿病の患者に対し優れ
た効果を有し、かつ副作用がなく安全に改善できるとの
知見を得て本発明を完成した。[0006] The inventors of the present invention have conducted extensive studies to achieve the above-mentioned object, and as a result, the Aspalathus linealis extract belonging to the legume family has an excellent effect on diabetic patients, and The present invention has been completed based on the finding that it can be safely improved without side effects.
【0007】本発明の有効成分は、アスパラサス・リネ
アリスの抽出液からなり、抽出法としては、アスパラサ
ス・リネアリスの葉または茎を水及び/または有機溶媒
で抽出し、該抽出液より抽出溶媒を留去する方法、また
はアスパラサス・リネアリスの葉または茎を粉砕するこ
とによって得ることができる。また、通常の日本茶、中
国茶、紅茶などの製法と同様に抽出してもよい。The active ingredient of the present invention comprises an extract of Aspalathus linealis. As an extraction method, leaves or stems of Aspalathus linealis are extracted with water and / or an organic solvent, and the extraction solvent is extracted from the extract. Can be obtained by distilling off or by crushing leaves or stems of Aspalathus linealis. In addition, it may be extracted in the same manner as in the production method of ordinary Japanese tea, Chinese tea, black tea and the like.
【0008】水で抽出する場合には、アスパラサス・リ
ネアリスの50〜1000倍の水を加え、沸騰後、さら
に5〜30分程度沸騰抽出するのが好ましい。また、通
常の茶と同様抽出するときは、アスパラサス・リネアリ
スの乾燥葉の50〜500倍の80〜100度の湯で3
〜30分程度放置して抽出液を得る。In the case of extraction with water, it is preferable to add 50 to 1000 times as much water as Aspalathus linealis, boil and then carry out boiling extraction for about 5 to 30 minutes. Also, when extracting in the same way as ordinary tea, use 3 to 50 times the hot water of 80 to 100 degrees, which is 50 to 500 times the dry leaves of Aspalathus linearis.
Leave for about 30 minutes to obtain an extract.
【0009】有機溶媒の具体例としては、メタノール、
エタノール、アセトン等が挙げられ、抽出にあたっては
温時抽出等慣用手段を用いることができる。また、抽出
液の分離も、デカンテーションや遠心分離等の慣用手段
を用いることができる。Specific examples of the organic solvent include methanol,
Ethanol, acetone and the like can be mentioned, and conventional means such as warm extraction can be used for extraction. Further, for the separation of the extract, conventional means such as decantation or centrifugation can be used.
【0010】抽出溶媒の留去も凍結乾燥等の慣用手段を
用いることができる。また、アスパラサス・リネアリス
そのものを粉砕し、粉末化して用いることもできる。A conventional means such as freeze-drying can be used for distilling off the extraction solvent. Also, Aspalathus linealis itself can be crushed and powdered for use.
【0011】本発明は、混合してそのまま溶液、粉末顆
粒、錠剤、乳剤、ゼリー状など任意の形態で単独投与、
または他の飲食物に混合して飲食することもできる。According to the present invention, a mixture is directly administered in any form such as a solution, powder granules, tablets, emulsions or jellies.
Alternatively, it can be mixed with other foods and drinks.
【0012】投与量は、対象となる疾患の種類、程度に
より異なるが、飲料として常用する場合には、1〜5g
乾燥葉/1溶液を100ml〜1500ml/日飲食す
るのが好ましい。The dose varies depending on the type and degree of the target disease, but in the case of regular use as a drink, 1 to 5 g
It is preferable to eat and drink 100 ml to 1500 ml / day of the dried leaf / 1 solution.
【0013】アスパラサス・リネアリスは、ラットに対
する急性毒性試験で死亡例は皆無であり、生化学血液検
査および病理組織学的検査においても異常が認められな
かった。[0013] Aspalathus linealis showed no death in an acute toxicity test in rats, and no abnormality was observed in biochemical blood tests and histopathological tests.
【0014】[0014]
【効果】本発明は、ヒトを含む哺乳動物の糖尿病の疾患
を副作用無く、迅速に改善治療することができる。The present invention can rapidly improve and treat diabetic diseases of mammals including humans without side effects.
【0015】[0015]
製造例 採取したアスパラサス・リネアリスの葉(茎つき)を、
5mm長に切断後、ローリング、酵素醗酵、天日乾燥の
工程を経て乾燥葉とする。乾燥葉4gを水1.5リット
ルで15分間沸騰させ抽出液を得た。Production example Collected Aspalathus linealis leaves (with stem)
After cutting to a length of 5 mm, dried leaves are subjected to the steps of rolling, enzyme fermentation, and sun drying. 4 g of dried leaves were boiled with 1.5 liters of water for 15 minutes to obtain an extract.
【0016】実施例1 製造例で得た抽出液を表1に示した患者に1日200m
Lから1000mL飲ませ、症状の改善を調べた。結果
を表1に示す。Example 1 The extract obtained in the production example was applied to the patients shown in Table 1 at 200 m per day.
1000 mL of L was given to examine the improvement of symptoms. The results are shown in Table 1.
【表1】 [Table 1]
【0017】アスパラサス・リネアリスの化学分析結果
は下記の通りである。 鉄 23.40mg/100g カルシウム 187.00mg/100g カリウム 398.00mg/100g マグネシウム 207.00mg/100g 銅 2.25ppm 亜鉛 6.74ppm セレン 0.13ppm ビタミンE 17.00mg/100g たんぱく質 8.00% フラボノイド 41.00mg/100g 抗酸化能・SOD様力価 69,000unit/g 酸不溶性蛋白成分 150mg/100g 香気成分 100mg/100g 糖含有化合物 690mg/100g The results of chemical analysis of Aspalathus linealis are as follows. Iron 23.40 mg / 100 g Calcium 187.00 mg / 100 g Potassium 398.00 mg / 100 g Magnesium 207.00 mg / 100 g Copper 2.25 ppm Zinc 6.74 ppm Selenium 0.13 ppm Vitamin E 17.00 mg / 100 g Protein 8.00% Flavonoids 41 0.000 mg / 100 g Antioxidant / SOD-like potency 69,000 unit / g Acid-insoluble protein component 150 mg / 100 g Aroma component 100 mg / 100 g Sugar-containing compound 690 mg / 100 g
【0018】また香気成分として、カルボニル化合物
(15%)、カロチノイド分解物(17%)、炭素数2
〜12の有機酸(22%)、フェノール化合物(13
%)、芳香族含酸素化合物(7%)、芳香族炭化水素
(5.5%)、テルペノイド(4%)などを含有する。
なお、酸不溶性蛋白質とは比較的分子量の大きな蛋白成
分である。As aroma components, carbonyl compound (15%), carotenoid decomposition product (17%), carbon number 2
~ 12 organic acids (22%), phenolic compounds (13
%), Aromatic oxygen-containing compounds (7%), aromatic hydrocarbons (5.5%), terpenoids (4%) and the like.
The acid-insoluble protein is a protein component having a relatively large molecular weight.
Claims (1)
成分とする糖尿病改善治療剤1. A therapeutic agent for diabetes mellitus comprising an Aspalathus linealis extract as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4084730A JPH05246875A (en) | 1992-03-06 | 1992-03-06 | Agent for improving and treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4084730A JPH05246875A (en) | 1992-03-06 | 1992-03-06 | Agent for improving and treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH05246875A true JPH05246875A (en) | 1993-09-24 |
Family
ID=13838812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4084730A Pending JPH05246875A (en) | 1992-03-06 | 1992-03-06 | Agent for improving and treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH05246875A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008156264A (en) * | 2006-12-22 | 2008-07-10 | Daishoo:Kk | Postprandial hyperglycemia and blood uric acid lowering effect of rooibos tea |
| WO2008110551A1 (en) | 2007-03-12 | 2008-09-18 | Zadec Aps | An anti-diabetic extract of rooibos |
-
1992
- 1992-03-06 JP JP4084730A patent/JPH05246875A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008156264A (en) * | 2006-12-22 | 2008-07-10 | Daishoo:Kk | Postprandial hyperglycemia and blood uric acid lowering effect of rooibos tea |
| WO2008110551A1 (en) | 2007-03-12 | 2008-09-18 | Zadec Aps | An anti-diabetic extract of rooibos |
| JP2010520913A (en) * | 2007-03-12 | 2010-06-17 | サズセ アーペーエス | Rooibos anti-diabetic extract |
| EP2368560A1 (en) * | 2007-03-12 | 2011-09-28 | Zadec ApS | An anti-diabetic extract of rooibos |
| US8877717B2 (en) | 2007-03-12 | 2014-11-04 | Zadec Aps | Anti-diabetic extract of rooibos |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20160007728A (en) | Method for manufacturing garlic skin extract and food composition for preventing and alleviating diabetes prepared using the same | |
| JP2019502721A (en) | Hangover composition | |
| CN103584091B (en) | A kind of guarantor with raising immunity, hypolipemic function builds food and preparation method thereof | |
| JPH05246866A (en) | Agent for stimulating cerebral metabolism and for improving cerebral function | |
| JP3334725B2 (en) | Accelerator for reducing alcohol in the body, its metabolites and oral freshener | |
| JPH06199695A (en) | Agent for amelioration and treatment of diabetes | |
| KR100377313B1 (en) | Method Of Fabricating Green tea Extractive | |
| JP2895298B2 (en) | Active oxygen scavenging / removal agent | |
| JPH0840923A (en) | Nutrient-supplying agent | |
| JPH05246875A (en) | Agent for improving and treating diabetes | |
| JP2004352626A (en) | Anti-cholesterol agent containing plant-derived components | |
| JP3167777B2 (en) | Antiviral, antibacterial and bactericide | |
| JP2724524B2 (en) | Constipation improvement / treatment agent | |
| JPH04300836A (en) | Hepatic dysfunction preventive agent and functional food having preventive action on hepatic dysfunction | |
| KR100337472B1 (en) | Health food beverage composition containing prickly pear extract | |
| JP3167776B2 (en) | Anticancer / anticancer agent | |
| JP3435415B2 (en) | Foods with antihyperlipidemic function | |
| CN108077485A (en) | A kind of blue or green money willow herbal tea and preparation method thereof | |
| JPH05246873A (en) | Agent for improving hepatic function and for preventing hangover | |
| JP3154544B2 (en) | Inflammatory disease improving therapeutic agent | |
| JPH05246871A (en) | Agent for improving and treating anemia | |
| JPH05271057A (en) | Improving and curing agent for rheumatism | |
| JPH05271058A (en) | Improving and curing agent for cataract | |
| CN107334913B (en) | Black garlic extract and preparation method and application thereof | |
| CA2291974C (en) | Composition comprising panax pseudo ginseng and eucommiae ulmoides |